KRAS and non-small cell lung carcinoma: Based on the results of the phase 2 CodeBreaK 100 trial, a new drug application was recently submitted to FDA for sotorasib for the treatment of patients with KRAS G12C-mutated locally advanced or metastatic NSCLC after at least one previous systemic therapy attempt [4].